The DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Open accessAbstract
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three decades ago, and activating RET rearrangements and mutations have since been identified as actionable drivers of oncogenesis. Several multikinase inhibitors with activity against RET have been explored in the clinic, and confirmed responses to targeted therapy with these agents have been observed in patients with RET-rearranged lung cancers or RET-mutant thyroid cancers. Nevertheless, response rates to RET-directed therapy are modest compared with those achieved using targeted therapies matched to other oncogenic drivers of solid tumours, such as sensitizing EGFR or BRAFV600E mutations, or ALK or ROS1 rearrangements. To date, no RET-directed targeted therapeutic has received regulatory approval for the treatment of molecularly defined populations of patients with RET-mutant or RET-rearranged solid tumours. In this Review, we discuss how emerging data have informed the debate over whether the limited success of multikinase inhibitors with activity against RET can be attributed to the tractability of RET as a drug target or to the lack, until 2017, of highly specific inhibitors of this oncoprotein in the clinic. We emphasize that novel approaches to targeting RET-dependent tumours are necessary to improve the clinical efficacy of single-agent multikinase inhibition and, thus, hasten approvals of RET-directed targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
RetractedGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
The GDNF family: Signalling, biological functions and therapeutic value
Airaksinen, M. S., & Saarma, M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn812 · Cited by 1,828
Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret
Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F., & Pachnis, V. (1994) · Nature · doi:10.1038/367380a0 · Cited by 1,614
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Self-citationLong, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.-J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,399
Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Self-citationHofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo-Jack, I., Gadgeel, S., Schultz, K., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,148
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Ports, G., Fusco, A., & Vecchiot, G. (1990) · Cell · doi:10.1016/0092-8674(90)90659-3 · Cited by 959
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 911
Planchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2673 · Cited by 869
Activation of a novel human transforming gene, ret, by DNA rearrangement
Takahashi, M., Ritz, J., & Cooper, G. M. (1985) · Cell · doi:10.1016/0092-8674(85)90115-1 · Cited by 854
Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B
Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. (1995) · Science · doi:10.1126/science.7824936 · Cited by 841
KIF5B-RET fusions in lung adenocarcinoma
Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2644 · Cited by 834
Hatakeyama, S. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3139 · Cited by 802
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798
Wu, Y.-L., Zhou, C., Liam, C.-K., Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., Han, B., Chen, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv270 · Cited by 738
Han, J.-Y., Park, K., Kim, S.-W., Lee, D. H., Kim, H. Y., Kim, H. T., Ahn, M. J., Yun, T., Ahn, J. S., Suh, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8456 · Cited by 736
Neurturin, a relative of glial-cell-line-derived neurotrophic factor
Kotzbauer, P. T., Lampe, P. A., Heuckeroth, R. O., Golden, J. P., Creedon, D. J., Johnson Jr, E. M., & Milbrandt, J. (1996) · Nature · doi:10.1038/384467a0 · Cited by 710
Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Muñoz, H., & Fagin, J. A. (1997) · PubMed · Cited by 666
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D., Kwok, J. B. J., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 652
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
Wiesner, T., He, J., Yelensky, R., Esteve-Puig, R., Botton, T., Yeh, I., Lipson, D., Otto, G., Brennan, K., Murali, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4116 · Cited by 649
Baloh, R. H., Tansey, M. G., Lampe, P. A., Fahrner, T. J., Enomoto, H., Simburger, K. S., Leitner, M. L., Araki, T., Johnson, E. M., & Milbrandt, J. (1998) · Neuron · doi:10.1016/s0896-6273(00)80649-2 · Cited by 588
Carlomagno, F., Vitagliano, D., Guida, T., Ciardiello, F., Tortora, G., Vecchio, G., Ryan, A. J., Fontanini, G., Fusco, A., & Santoro, M. M. (2002) · PubMed · Cited by 569
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
Wang, R., Hu, H., Pan, Y., Li, Y., Ye, T., Li, C., Luo, X., Wang, L., Li, H., Zhang, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1477 · Cited by 546
RET revisited: expanding the oncogenic portfolio
Mulligan, L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3680 · Cited by 513
Persephin, a Novel Neurotrophic Factor Related to GDNF and Neurturin
Milbrandt, J., de Sauvage, F. J., Fahrner, T. J., Baloh, R. H., Leitner, M. L., Tansey, M. G., Lampe, P. A., Heuckeroth, R. O., Kotzbauer, P. T., Simburger, K. S., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80453-5 · Cited by 495
RET/PTC Rearrangement in Thyroid Tumors
Nikiforov, Y. E. (2002) · Endocrine Pathology · doi:10.1385/ep:13:1:03 · Cited by 489
Drilon, A., Rekhtman, N., Arcila, M., Wang, L., Ni, A., Albano, M., Van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30562-9 · Cited by 484
Self-citationBAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
Proximity of Chromosomal Loci That Participate in Radiation-Induced Rearrangements in Human Cells
Nikiforova, M. N., Stringer, J. R., Blough, R., Medvedovic, M., Fagin, J. A., & Nikiforov, Y. E. (2000) · Science · doi:10.1126/science.290.5489.138 · Cited by 468
RET tyrosine kinase signaling in development and cancer
Arighi, E., Borrello, M. G., & Sariola, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.010 · Cited by 468
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Drilon, A., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P., Ross, J., Miller, V., Ginsberg, M., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 464
Self-citationThe landscape and therapeutic relevance of cancer-associated transcript fusions
Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., & Verhaak, R. G. W. (2015) · Oncogene · doi:10.1038/onc.2014.406 · Cited by 450
Lacouture, M. E., Anadkat, M. J., Bensadoun, R.-J., Bryce, J., Chan, A., Epstein, J. B., Eaby-Sandy, B., Murphy, B. A., & MASCC Skin Toxicity Study Group (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1197-6 · Cited by 444
Carr, L. L., Mankoff, D. A., Goulart, B. H., Eaton, K. D., Capell, P. T., Kell, E. M., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 422
Herbst, R. S., Sun, Y., Eberhardt, W. E., Germonpré, P., Saijo, N., Zhou, C., Wang, J., Li, L., Kabbinavar, F., Ichinose, Y., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70132-7 · Cited by 415
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Lam, E. T., Ringel, M. D., Kloos, R. T., Prior, T. W., Knopp, M. V., Liang, J., Sammet, S., Hall, N. C., Wakely, P. E., Vasko, V. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0068 · Cited by 377
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.9352 · Cited by 360
Self-citationGlial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence
Ibiza, S., García-Cassani, B., Ribeiro, H., Carvalho, T., Almeida, L., Marques, R., Misic, A. M., Bartow-McKenney, C., Larson, D. M., Pavan, W. J., et al. (2016) · Nature · doi:10.1038/nature18644 · Cited by 358
The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease
Eppig, J. T., Blake, J. A., Bult, C. J., Kadin, J. A., Richardson, J. E., & The Mouse Genome Database Group (2015) · Nucleic Acids Research · doi:10.1093/nar/gku967 · Cited by 357
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Romei, C., Ciampi, R., & Elisei, R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.11 · Cited by 352
Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7815 · Cited by 340
Mechanism of Activation of the ret Proto-oncogene by Multiple Endocrine Neoplasia 2A Mutations
Asai, N., Iwashita, T., Matsuyama, M., & Takahashi, M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1613 · Cited by 340
Trupp, M., Scott, R., Whittemore, S. R., & Ibáñez, C. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.30.20885 · Cited by 318
Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D. M., Hechtman, J., Wei, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw042 · Cited by 306
Self-citationStructure and Chemical Inhibition of the RET Tyrosine Kinase Domain
Knowles, P. P., Murray-Rust, J., Kjær, S., Scott, R. P., Hanrahan, S., Santoro, M., Ibáñez, C. F., & McDonald, N. Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605604200 · Cited by 302
Yoh, K., Seto, T., Satouchi, M., Nishio, M., Yamamoto, N., Murakami, H., Nogami, N., Matsumoto, S., Kohno, T., Tsuta, K., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30322-8 · Cited by 294
Tyrosine kinase gene rearrangements in epithelial malignancies
Shaw, A. T., Hsu, P. P., Awad, M. M., & Engelman, J. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3612 · Cited by 292
Okamoto, K., Kodama, K., Takase, K., Sugi, N. H., Yamamoto, Y., Iwata, M., & Tsuruoka, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.007 · Cited by 288
Tyrosine kinase receptor RET is a key regulator of Peyer’s Patch organogenesis
Veiga-Fernandes, H., Coles, M. C., Foster, K. E., Patel, A., Williams, A., Natarajan, D., Barlow, A., Pachnis, V., & Kioussis, D. (2007) · Nature · doi:10.1038/nature05597 · Cited by 285
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 282
Drilon, A., Wang, L., Arcila, M. E., Balasubramanian, S., Greenbowe, J. R., Ross, J. S., Stephens, P., Lipson, D., Miller, V. A., Kris, M. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2683 · Cited by 274
Self-citationHwang, D.-Y., Dworschak, G. C., Kohl, S., Saisawat, P., Vivante, A., Hilger, A. C., Reutter, H. M., Soliman, N. A., Bogdanovic, R., Kehinde, E. O., et al. (2014) · Kidney International · doi:10.1038/ki.2013.508 · Cited by 263
Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis
de Graaff, E., Srinivas, S., Kilkenny, C., D'Agati, V., Mankoo, B. S., Costantini, F., & Pachnis, V. (2001) · Genes & Development · doi:10.1101/gad.205001 · Cited by 251
RET/PTC oncogene activation is an early event in thyroid carcinogenesis.
Viglietto, G., Chiappetta, G., Martínez-Tello, F. J., Fukunaga, F., Tallini, G., Rigopoulou, D., Visconti, R., Mastro, A., Santoro, M., & Fusco, A. (1995) · PubMed · Cited by 248
Schlumberger, M., Jarzab, B., Cabanillas, M. E., Robinson, B., Pacini, F., Ball, D. W., McCaffrey, J., Newbold, K., Allison, R., Martins, R. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1127 · Cited by 247
Lee, S.-H., Lee, J.-K., Ahn, M.-J., Kim, D.-W., Sun, J.-M., Keam, B., Kim, T. M., Heo, D. S., Ahn, J. S., Choi, Y.-L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw559 · Cited by 244
Vega, Q. C., Worby, C. A., Lechner, M. S., Dixon, J. E., & Dressler, G. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10657 · Cited by 242
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522758 · Cited by 242
Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M. C., Niederle, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx479 · Cited by 240
Cancer phenomics: RET and PTEN as illustrative models
Zbuk, K. M., & Eng, C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2037 · Cited by 239
Santoro, M., Chiappetta, G., Cerrato, A., Salvatore, D., Zhang, L., Manzo, G., Picone, A., Portella, G., Santelli, G., Vecchio, G., et al. (1996) · PubMed · Cited by 234
Chi, X., Michos, O., Shakya, R., Riccio, P., Enomoto, H., Licht, J. D., Asai, N., Takahashi, M., Ohgami, N., Kato, M., et al. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.07.013 · Cited by 233
Lee, J. S., Hirsh, V., Park, K., Qin, S., Blajman, C. R., Perng, R.-P., Chen, Y.-M., Emerson, L., Langmuir, P., & Manegold, C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1709 · Cited by 230
VEGF Inhibition, Hypertension, and Renal Toxicity
Hayman, S. R., Leung, N., Grande, J. P., & Garovic, V. D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0242-z · Cited by 230
Tsuzuki, T., Takahashi, M., Asai, N., Iwashita, T., Matsuyama, M., & Asai, J. (1995) · PubMed · Cited by 225
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
Lacouture, M. E., Duvic, M., Hauschild, A., Prieto, V. G., Robert, C., Schadendorf, D., Kim, C. C., McCormack, C. J., Myskowski, P. L., Spleiss, O., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0333 · Cited by 218
Kramer, E. R., Aron, L., Ramakers, G. M. J., Seitz, S., Zhuang, X., Beyer, K., Smidt, M. P., & Klein, R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050039 · Cited by 209
Zhu, Z., Ciampi, R., Nikiforova, M. N., Gandhi, M., & Nikiforov, Y. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1006 · Cited by 209
Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Nakaoku, T., Tsuta, K., Ichikawa, H., Shiraishi, K., Sakamoto, H., Enari, M., Furuta, K., Shimada, Y., Ogiwara, H., Watanabe, S.-I., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0107 · Cited by 206
RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
Tsuta, K., Kohno, T., Yoshida, A., Shimada, Y., Asamura, H., Furuta, K., & Kushima, R. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.36 · Cited by 202
Chipping away at the lung cancer genome
Pao, W., & Hutchinson, K. E. (2012) · Nature Medicine · doi:10.1038/nm.2697 · Cited by 192
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Brea, E. J., Oh, C. Y., Manchado, E., Budhu, S., Gejman, R. S., Mo, G., Mondello, P., Han, J. E., Jarvis, C. A., Ulmert, D., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0177 · Cited by 173
Alectinib Shows Potent Antitumor Activity against RET -Rearranged Non–Small Cell Lung Cancer
Kodama, T., Tsukaguchi, T., Satoh, Y., Yoshida, M., Watanabe, Y., Kondoh, O., & Sakamoto, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0274 · Cited by 172
Worby, C. A., Vega, Q. C., Zhao, Y., Chao, H. H.-J., Seasholtz, A. F., & Dixon, J. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23619 · Cited by 168
Hoffmann, P., & Warner, B. (2006) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2005.07.003 · Cited by 167
Imatinib mesylate causes hypopigmentation in the skin
Tsao, A. S., Kantarjian, H., Cortes, J., O'Brien, S., & Talpaz, M. (2003) · Cancer · doi:10.1002/cncr.11812 · Cited by 161
Melillo, R. M., Santoro, M. M., Ong, S. H., Billaud, M., Fusco, A., Hadari, Y. R., Schlessinger, J., & Lax, I. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4177-4187.2001 · Cited by 152
Plaza-Menacho, I., Morandi, A., Robertson, D. M., Pancholi, S., Drury, S., Dowsett, M., Martin, L.-A., & Isacke, C. M. (2010) · Oncogene · doi:10.1038/onc.2010.209 · Cited by 149
Azad, N. S., Aragon‐Ching, J. B., Dahut, W. L., Gutierrez, M. E., Figg, W. D., Jain, L., Steinberg, S. M., Turner, M. L. C., Kohn, E. C., & Kong, H. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1141 · Cited by 145
Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
Ji, J. H., Oh, Y. L., Hong, M. E., Yun, J. W., Lee, H.-W., DeokGeun, K., Ji, Y., Duk-Hwan, K., Park, W., Shin, H., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005467 · Cited by 139
Michiels, F.-M., Chappuis, S., Caillou, B., Pasini, A., Talbot, M., Monier, R., Lenoir, G., Feunteun, J., & Billaud, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3330 · Cited by 138
Bentzien, F., Zuzow, M., Heald, N., Gibson, A., Shi, Y., Goon, L. H., Yu, P., Engst, S., Zhang, W., Huang, D., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0137 · Cited by 137
Novel Mechanism of Regulation of Rac Activity and Lamellipodia Formation by RET Tyrosine Kinase
Fukuda, T., Kiuchi, K., & Takahashi, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200643200 · Cited by 134
Morandi, A., Martin, L., Gao, Q., Pancholi, S., Mackay, A. G., Robertson, D. M., Zvelebil, M., Dowsett, M., Plaza-Menacho, I., & Isacke, C. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4265 · Cited by 132
Leeman‐Neill, R. J., Brenner, A. V., Little, M. P., Ti, B., HATCH, M. C., Zurnadzhy, L. Y., Mabuchi, K., Tronko, M. D., & Nikiforov, Y. E. (2013) · Cancer · doi:10.1002/cncr.27893 · Cited by 131
Central Role of RET in Thyroid Cancer
Santoro, M. M., & Carlomagno, F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009233 · Cited by 126
Congenital central hypoventilation syndrome and Hirschsprung's disease
Croaker, G. D. H., Shi, E., Simpson, E., Cartmill, T. B., & Cass, D. T. (1998) · Archives of Disease in Childhood · doi:10.1136/adc.78.4.316 · Cited by 126
Santoro, M., Melillo, R. M., Grieco, M., Berlingieri, M. T., Vecchio, G., & Fusco, A. (1993) · PubMed · Cited by 126
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
Drilon, A. E. D. C., Bergagnini, I., Delasos, L., Sabari, J. K., Woo, K. M., Plodkowski, A. J., Wang, L., Hellmann, M. D., Joubert, P., Sima, C. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw163 · Cited by 126
Self-citationBoulay, A., Breuleux, M., Stephan, C., Fux, C., Brisken, C., Fiche, M., Wartmann, M., Stumm, M., Lane, H. A., & Hynes, N. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5100 · Cited by 123
Patwardhan, P. P., Ivy, K. S., Musi, E., de Stanchina, E., & Schwartz, G. K. (2015) · Oncotarget · doi:10.18632/oncotarget.6547 · Cited by 121
The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function
Fonseca‐Pereira, D., Arroz‐Madeira, S., Rodrigues-Campos, M., Barbosa, I. A. M., Domingues, R. G., Bento, T., Almeida, A. R. M., Ribeiro, H., Potocnik, A. J., Enomoto, H., et al. (2014) · Nature · doi:10.1038/nature13498 · Cited by 120
Mutations of the RET-GDNF Signaling Pathway in Ondine's Curse
Amiel, J., Salomon, R., Attié‐Bitach, T., Pelet, A., Trang, H., Mokhtari, M., Gaultier, C., Münnich, A., & Lyonnet, S. (1998) · The American Journal of Human Genetics · doi:10.1086/301759 · Cited by 117
Ravaud, A., de la Fouchardière, C., Caron, P. J., Doussau, A., Cao, C. D., Asselineau, J., Rodien, P., Pouessel, D., Nicolli-Sire, P., Klein, M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.029 · Cited by 117
A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer
Lira, M. E., Choi, Y., Lim, S. M., Deng, S., Huang, D., Ozeck, M., Han, J., Jeong, J. Y., Shim, H. S., Cho, B. C., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.11.007 · Cited by 116
Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident
lto, T., Seyama, T., Iwamoto, S., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)93024-4 · Cited by 115
Carlomagno, F., Vitagliano, D., Guida, T., Basolo, F., Castellone, M. D., Melillo, R. M., Fusco, A., & Santoro, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021278 · Cited by 113
Loriot, Y., Perlemuter, G., Malka, D., Penault-Llorca, F. M., Boige, V., Deutsch, É., Massard, C., Armand, J. P., & Soria, J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1087 · Cited by 110
MEN2A-RET-induced cellular transformation by activation of STAT3
Schuringa, J. J., Wojtachnio, K., Hagens, W. I., Vellenga, E., Buys, C. H. C. M., Hofstra, R. M. W., & Kruijer, W. (2001) · Oncogene · doi:10.1038/sj.onc.1204715 · Cited by 109
Ballerini, P. F., Struski, S., Cresson, C., Prade, N., Toujani, S., Deswarte, C., Dobbelstein, S., Petit, A., Lapillonne, H., Gautier, E., et al. (2012) · Leukemia · doi:10.1038/leu.2012.109 · Cited by 107
Differential RET Signaling Pathways Drive Development of the Enteric Lymphoid and Nervous Systems
Patel, A. J., Harker, N., Moreira-Santos, L., Ferreira, M. M., Alden, K., Timmis, J., Foster, K., Garefalaki, A., Pachnis, P., Andrews, P. S., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002734 · Cited by 106
Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy
Plaza-Menacho, I., Mologni, L., & McDonald, N. Q. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.03.032 · Cited by 104
Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
Lin, J. J., Kennedy, E., Sequist, L. V. D., Brastianos, P. K., Goodwin, K. E., Stevens, S. E., Wanat, A. C., Stober, L. L., Digumarthy, S. R., Engelman, J. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.126 · Cited by 104
Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad
Matsubara, D., Kanai, Y., Ishikawa, S., Ohara, S., Yoshimoto, T., Sakatani, T., Oguni, S., Tamura, T., Kataoka, H., Endo, S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182721ed1 · Cited by 103
Fitze, G., Cramer, J. P., Ziegler, A., Schierz, I. A. M., Schreiber, M., Kuhlisch, E., Roesner, D., & Schackert, H. K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08218-1 · Cited by 101
RET proto-oncogene is important for the development of respiratory CO2 sensitivity
Burton, M. D., Kawashima, A., Brayer, J., Kazemi, H., Shannon, D. C., Schuchardt, A., Costantini, F. D., Pachnis, V., & Kinane, T. B. (1997) · Journal of the Autonomic Nervous System · doi:10.1016/s0165-1838(97)00002-7 · Cited by 101
DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells
Gandhi, M., Dillon, L. W., Pramanik, S., Nikiforov, Y. E., & Wang, Y.-H. (2010) · Oncogene · doi:10.1038/onc.2009.502 · Cited by 98
Krystal, G. W., Honsawek, S., Kiewlich, D., Liang, C., Vasile, S., Sun, L., McMahon, G., & Lipson, K. E. (2001) · PubMed · Cited by 97
Chatterjee, R., Ramos, E., Hoffman, M., VanWinkle, J., Martin, D. R., Davis, T. K., Hoshi, M., Hmiel, S. P., Beck, A., Hruska, K. A., et al. (2012) · Human Genetics · doi:10.1007/s00439-012-1181-3 · Cited by 96
Murakami, H., Iwashita, T., Asai, N., Shimono, Y., Iwata, Y., Kawai, K., & Takahashi, M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1186 · Cited by 96
Plaza-Menacho, I., Koster, R., van der Sloot, A. M., Quax, W. J., Osinga, J., van der Sluis, T., Hollema, H., Burzynski, G. M., Gimm, O., Buys, C. H. C. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2363 · Cited by 94
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
Mologni, L., Redaelli, S., Morandi, A., Plaza-Menacho, I., & Gambacorti-Passerini, C. B. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.06.025 · Cited by 87
Croyle, M., Akeno, N., Knauf, J. A., Fabbro, D., Chen, X., Baumgartner, J. E., Lane, H. A., & Fagin, J. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0413 · Cited by 86
RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma
Corvi, R., Berger, N., Balczon, R., & Romeo, G. (2000) · Oncogene · doi:10.1038/sj.onc.1203772 · Cited by 86
Acton, D. S., Velthuyzen, D., Lips, C. J. M., & Höppener, J. W. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203648 · Cited by 85
Verbeek, H. H. G., Alves, M. M., de Groot, J. B., Osinga, J., Plukker, J. T. M., Links, T. P., & Hofstra, R. M. W. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2381 · Cited by 84
Wang, J., Knauf, J. A., Basu, S., Puxeddu, E., Kuroda, H., Santoro, M., Fusco, A., & Fagin, J. A. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0041 · Cited by 83
Nelson-Taylor, S. K., Le, A. T., Yoo, M., Schubert, L., Mishall, K. M., Doak, A. E., Varella‐Garcia, M., Tan, A. C., & Doebele, R. C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0008 · Cited by 83
Wang, X. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.10.008 · Cited by 81
HOOK3-RET : a novel type of RET/PTC rearrangement in papillary thyroid carcinoma
Ciampi, R., Giordano, T. J., Wikenheiser‐Brokamp, K. A., Koenig, R. J., & Nikiforov, Y. E. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0039 · Cited by 79
Salassidis, K., Bruch, J., Zitzelsberger, H. F., Lengfelder, E., Kellerer, A. M., & Bauchinger, M. (2000) · PubMed · Cited by 78
Jasim, S., Ying, A. K., Waguespack, S. G., et al. (2010) · Thyroid · doi:10.1089/thy.2010.0328 · Cited by 77
Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma
Huang, Q., Schneeberger, V. E., Luetteke, N., Jin, C., Afzal, R., Budzevich, M. M., Makanji, R. J., Martinez, G. V., Shen, T., Zhao, L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0258 · Cited by 77
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Vaishnavi, A., Schubert, L., Rix, U., Marek, L. A., Le, A. T., Keysar, S. B., Glogowska, M. J., Smith, M. A., Kako, S. L., Sumi, N. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0109 · Cited by 76
Vitagliano, D., Falco, V. D., Tamburrino, A., Coluzzi, S., Troncone, G., Chiappetta, G., Ciardiello, F., Tortora, G., Fagin, J. A., Ryan, A. J., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0292 · Cited by 74
Suzuki, M., Makinoshima, H., Matsumoto, S., Suzuki, A., Mimaki, S., Matsushima, K., Yoh, K., Goto, K., Suzuki, Y., Ishii, G., et al. (2013) · Cancer Science · doi:10.1111/cas.12175 · Cited by 73
Salvatore, D., Melillo, R. M., Monaco, C., Visconti, R., Fenzi, G., Vecchio, G., Fusco, A., & Santoro, M. M. (2001) · PubMed · Cited by 71
Subbiah, V., Berry, J., Roxas, M., Guha‐Thakurta, N., Subbiah, I. M., Ali, S. M., McMahon, C., Miller, V. A., Cascone, T., Pai, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.04.004 · Cited by 71
Beldjord, C., Desclaux-Arramond, F., Raffin‐Sanson, M., Corvol, J., de Keyzer, Y., LUTON, J. P., Plouin, P., & BERTAGNA, X. Y. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.7.7608256 · Cited by 71
Arcand, A. (1948) · PubMed · Cited by 71
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
Li, G. G., Somwar, R., Joseph, J. D., Smith, R. S., Hayashi, T., Martin, L., Franovic, A., Schairer, A., Martin, E. S., Riely, G. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1887 · Cited by 70
Self-citationRET gene is a major risk factor for Hirschsprung’s disease: a meta-analysis
Tomuschat, C., & Puri, P. (2015) · Pediatric Surgery International · doi:10.1007/s00383-015-3731-y · Cited by 68
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
Plenker, D., Riedel, M., Brägelmann, J., Dammert, M. A., Chauhan, R., Knowles, P. P., Lorenz, C., Keul, M., Bührmann, M., Pagel, O., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah6144 · Cited by 67
Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma
Mizukami, T., Shiraishi, K., Shimada, Y., Ogiwara, H., Tsuta, K., Ichikawa, H., Sakamoto, H., Kato, M., Shibata, T., Nakano, T., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000135 · Cited by 66
Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells
Gild, M. L., Landa, I., Ryder, M. M., Ghossein, R. A., Knauf, J. A., & Fagin, J. A. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0085 · Cited by 65
Monaco, C., Visconti, R., Barone, M. V., Pierantoni, G. M., Berlingieri, M. T., Lorenzo, C. D., Mineo, A., Vecchio, G., Fusco, A., & Santoro, M. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204127 · Cited by 65
Geater, S. L., Xu, C., Zhou, C., Hu, C., Feng, J., Lü, S., Huang, Y., Li, W., Hou, M., Shi, J. H., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000517 · Cited by 61
Lin, C., Wang, S., Xie, W., Zheng, R., Gan, Y., & Chang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10985 · Cited by 60
KIF5B‐RET fusions in Chinese patients with non–small cell lung cancer
Cai, W., Su, C., Li, X., Fan, L., Zheng, L.-M., Fei, K., & Zhou, C. (2013) · Cancer · doi:10.1002/cncr.27940 · Cited by 59
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
Horiike, A., Takeuchi, K., Uenami, T., Kawano, Y., Tanimoto, A., Kaburaki, K., Tambo, Y., Kudo, K., Yanagitani, N., Ohyanagi, F., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.12.011 · Cited by 59
Inhibition of RET tyrosine kinase by SU5416
Mologni, L., Sala, E., Cazzaniga, S., Rostagno, R., Kuoni, T., Puttini, M., Bain, J., Cleris, L., Redaelli, S., Riva, B., et al. (2006) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01999 · Cited by 58
Transcript Level Modulates the Inherent Oncogenicity of RET/PTC Oncoproteins
Richardson, D. S., Gujral, T. S., Peng, S. S., Asa, S. L., & Mulligan, L. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4425 · Cited by 56
Spanheimer, P. M., Park, J. M., Askeland, R. W., Kulak, M. V., Woodfield, G. W., Andrade, J. P. D., Cyr, A. R., Sugg, S. L., Thomas, A., & Weigel, R. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2221 · Cited by 53
An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
Lim, S. M., Chung, W. Y., Nam, K., Kang, S., Lim, J. Y., Kim, H., Shin, S. H., Sun, J.-M., Kim, S.-G., Kim, J.-H., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.020 · Cited by 52
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis
Saito, M., Ishigame, T., Tsuta, K., Kumamoto, K., Imai, T., & Kohno, T. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu158 · Cited by 50
EGF Induced RET Inhibitor Resistance inCCDC6-RETLung Cancer Cells
Chang, H. K., Sung, J. H., Moon, S. U., Kim, H.-S., Kim, J. W., & Lee, J. S. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.1.9 · Cited by 42
Maeda, K., Murakami, H., Yoshida, R., Ichihara, M., Abe, A., Hirai, M., Murohara, T., & Takahashi, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.095 · Cited by 37
Wang, C., Mayer, J. A., Mazumdar, A., & Brown, P. H. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1775-9 · Cited by 37
Andreozzi, F., Melillo, R. M., Carlomagno, F., Oriente, F., Miele, C., Fiory, F., Santopietro, S., Castellone, M. D., Bèguinot, F., Santoro, M. M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206475 · Cited by 34
Functional characterization of a novel FGFR1OP‐RET rearrangement in hematopoietic malignancies
Bossi, D., Carlomagno, F., Pallavicini, I., Pruneri, G., Trubia, M., Raviele, P. R., Marinelli, A., Anaganti, S., Cox, M. C., Viale, G., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.11.004 · Cited by 33
Smith, J. A., Read, M. L., Hoffman, J., Brown, R., Bradshaw, B., Campbell, C., Cole, T. R. P., Navas, J. D., Eatock, F., Gundara, J. S., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw057 · Cited by 33
RET Rearrangements in Lung Adenocarcinoma and Radiation
Đačić, S., Luvison, A., Evdokimova, V. N., Kelly, L. M., Siegfried, J. M., Villaruz, L. C., Socinski, M. A., & Nikiforov, Y. E. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000015 · Cited by 26
FRMD4A / RET : A Novel RET Oncogenic Fusion Variant in Non–Small Cell Lung Carcinoma
Velcheti, V., Thawani, R., Khunger, M., Mukhopadhyay, S., Chute, D. J., Schrock, A. B., & Ali, S. M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.274 · Cited by 25
Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia
Jain, N., & O'Brien, S. M. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.01.006 · Cited by 21
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer
Ferrari, S. M., Motta, C. L., Sartini, S., Baldini, E., Materazzi, G., Politti, U., Ruffilli, I., Ulisse, S., Miccoli, P., Antonelli, A., et al. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151016124208 · Cited by 20
Subbiah, V., Gervais, R., Riely, G. J., Hollebecque, A., Blay, J., Felip, E., Schüler, M., Gonçalvès, A., Italiano, A., Keedy, V. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9074 · Cited by 12
Cited by
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005653 · Cited by 828
Self-citationBenayed, R., Offin, M., Mullaney, K., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R., Won, H., Chang, J., Halpenny, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0225 · Cited by 484
Self-citationSubbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A., Weiss, J., Takeda, M., Ohe, Y., Khan, S., Ohashi, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00541-1 · Cited by 449
Self-citationSelective RET kinase inhibition for patients with RET-altered cancers
Subbiah, V., Velcheti, V., Tuch, B. B., Ebata, K., Busaidy, N. L., Cabanillas, M. E., Wirth, L. J., Stock, S., Smith, S., Lauriault, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy137 · Cited by 425
Self-citationPrecision Targeted Therapy with BLU-667 for RET-Driven Cancers
Subbiah, V., Gainor, J. F., Rahal, R., Brubaker, J. D., Kim, J. L., Maynard, M., Hu, W., Cao, Q., Sheets, M. P., Wilson, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0338 · Cited by 396
Metadata
- Authors
- Drilon, A., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2017-11-14
- Volume
- 15
- Issue
- 3
- Pages
- 151-167
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2769006626
- Cited by
- 406
- References
- 186
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.